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Abstract Histoplasma capsulatum is responsible for histo-
plasmosis, a fungal disease with worldwide distribution that
can affect both immunocompromised and imunocompetent
individuals. During the highly active antiretroviral therapy
(HAART) era, morbidity and mortality due to histoplasmosis
remained a public heatlh problem in low-income and high-
income countries. The true burden of HIV-associated histo-
plasmosis is either not fully known or neglected since it is not
a notifiable disease. Progress has been made in DNA patterns
of strains and understanding of pathogenesis, and hopefully
these will help identify new therapeutic targets. Unfortunately,
histoplasmosis is still widely mistaken for multidrug-resistant
tuberculosis, leading to numerous avoidable deaths, even if
they are easily distinguishable. The new diagnostic tools and
therapeutics developments have still not been made available
in most endemic regions. Still, recent developments are prom-
ising because of their good clinical characteristics and also
because they will be commercially available and affordable.
This review of published data and gaps may help define and
guide future research.
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Introduction
Histoplasma capsulatum (H. capsulatum) is the etiologic
agent of histoplasmosis, a fungal disease that can affect both
immunocompromised and imunocompetent individuals. It
was first described in 1905 by S.T. Darling, concerning a case
that looked like disseminated tuberculosis in a patient origi-
nated from Martinique who was working at building the
Panama Canal [1].
Since then, histoplasmosis was described on five conti-
nents, with high and low endemicity areas. Thus, epidemio-
logic, clinical, paraclinical and therapeutic data are available
and have led to numerous publications by reference centers,
based on autochthonous cases in endemic areas [2–7] or
imported cases in non-endemic areas [8–10].
Labeled as the first respiratory fungal infection by some
authors, the public health burden of histoplasmosis differs
depending on whether the person is immunocompromised or
not. Among immunocompetent persons, apart from
histoplasmin test campaigns, few serologic prevalence studies
have been conducted in the general population. However,
some authors estimate that hundred of thousands cases occur
every year in the Ohio and Mississipi River regions. Mostly
asymptomatic and spontaneously self-limited, histoplasmosis
causes lowmorbidity and mortality among immunocompetent
patients [11].
Among immunocompromised patients, in the presence of
an acquired or congenital cellular immunity deficiency, histo-
plasmosis is responsible for an important morbidity and mor-
tality. At all ages, it is mostly fatal in the absence of appropri-
ate treatment. Following the first cases described in 1982 in
human immunodeficiency virus (HIV) infected patients in the
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USA, its extrapulmonary or disseminated form became an
acquired immunodeficiency syndrome (AIDS)-defining in-
fection in 1987 [12, 13].
During the last decades, morbidity and mortality from
histoplasmosis have increased because of the increase in the
number of immunocompromised persons. Although
immunosuppressors used in transplant patients or chronic
inflammatory diseases contribute to this increase, the greater
part of the problem is mostly attributable to the spread of the
HIV pandemic. [14]. The availability of highly active antire-
troviral therapy (HAART) and lipid formulations of
amphotericin B, the increased awareness of the problem by
some teams, and the development of rapid, noninvasive, di-
agnostic methods have led to a major impact on mortality by
histoplasmosis [15]. This progress was so spectacular that
some authors no longer consider histoplasmosis a problem
in the course of the HIV infection, considering instead that
research should focus on other causes of immunosuppression
associated with histoplasmosis [11, 16].
However, these developments are heterogeneous, and some
authors consider HIV-associated histoplasmosis a neglected
disease, notably in South America [17]. Evolving under the
radar of health authorities and research institutions, it is thought
to have caused several thousand deaths in the Amazon region
alone since the beginning of the epidemic [15].
Independently of the availability of HAART, histoplasmo-
sis in HIV-infected patients remains a public health problem
that is overlooked in numerous countries in endemic areas,
notably in South America. To tackle this problem, there are
important needs in terms of epidemiological knowledge,
health professionals becoming aware of it, diagnostic devel-
opment and availability of effective treatments at affordable
costs [17].
This review will consider the recent developments and
gaps regarding the epidemiological, diagnostic (clinical and
biological) and therapeutic aspects of histoplasmosis in HIV-
infected patients. The objective is to describe the current
situation in order to guide future research.
Taxonomy and Molecular Epidemiology
Historically, H. capsulatum was considered to be divided into
three varieties based on morphologic characteristics:
H. capsulatum var. capsulatum, mainly described in the
Americas; H. capsulatum var. duboisii, mainly described in
Africa; and H. capsulatum var. farciminosum, described in
equines from Africa and the Middle East [18].
The H. capsulatum species is not monophyletic and has
been recently subdivided into geographically distinct phylo-
genetic lineages [19]. Based on concordance of multiple gene
sequence genealogies, Histoplasma strains separate into at
least eight clades: North American class 1 (Nam1), North
American class 2 (Nam2), Latin American group A (LamA),
Latin American group B (LamB), Australian, Netherlands
(Indonesian), Eurasian, and African clades [20]. Seven of
these eight clades comprise genetically and geographically
distinct populations that can be regarded as phylogenetic
species. The single exception, the Eurasian clade, originated
fromwithin the Latin American group A clade.H. capsulatum
var. farciminosum was placed within the Eurasian clade. In
addition to the seven phylogenetic species, another seven
lineages represented by single isolates from Latin America
were identified [18, 20].
Interestingly, clinical differences in histoplasmosis disease
manifestation have been reported among the groups [19]. At
this time, histoplasmosis due to H. capsulatum var. duboisii
was considered a distinct entity, causing primarily cutaneous
and subcutaneous lesions rather than pulmonary involvement.
Unlike var. capsulatum and according to published data, var.
duboisii is still not considered as an AIDS-defining illness
[21]. Whether this manifestation is determined by genetic
differences in Histoplasma strains is unclear, since the taxo-
nomic placement of H. capsulatum var. duboisii has been
called into question by the finding of one var. capsulatum
isolate from South Africa (primarily causing pulmonary dis-
ease) that was placed in the African clade (var. duboisii-
containing) [19, 20]. This extends the results of earlier studies
that had shown that var. duboisii had mitochondrial DNA
restriction patterns identical to those of var. capsulatum strains
[18]. In the Americas, authors have reported mucocutaneous
tropism differences between North and South strains in HIV-
infected patients as linked with genetic differences in
Histoplasma strains [22, 23]. These findings didn’t reach
consensus, since a marked decrease of mucocutaneous man-
ifestation was observed by others during the HAART era,
concomitant to the opening of a laboratory specialized in
mycology [24, 25]. Other differences involving Nam1 and/
or Nam2 and/or Latin American strains, concerning either the
disease potential progression (acute or chronic) or the
Histoplasma strain infection potential according to the im-
mune status of the host (HIV-infected or not), have been
described in the Americas with contradictory results [19].
Multiple typing methods have been developed to study the
epidemiology ofH. capsulatum. Nowadays, molecular typing
methods are generally considered to have advantages over
phenotypic methods in terms of stability of genomic markers
and greater levels of type-ability. Several genotype-based
methods, such as hybridization of target genes (probes), chro-
mosomal DNA typing, restriction fragment length polymor-
phism (RFLP) analysis, random amplified polymorphic DNA
(RAPD) analysis, and sequencing, have been described for
H. capsulatum [26]. No single approach based onDNA assays
has been the dominant method. Nevertheless, the analysis of
concordance in the results obtained with different methods
using the same set of isolates showed great convergence [26].
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Thus, advances in the classification of H. capsulatum are
sustained by the results of several genetic analyses that sup-
port the high diversity of this dimorphic fungus, suggesting
diversity among strains in virulence, infectivity, pathogenesis
and relationship to the immune status of the host [19]. But all
these findings are based on relatively small sample size, and
studies are required in order to explore the functional conse-
quences of these variations on histoplasmosis pathogenesis in
HIV-infected patients.
Epidemiology
H. capsulatum is a fungus that is distributed worldwide, en-
demic to geographically limited areas, according to local envi-
ronmental conditions favorable to its development [27]. Since
histoplasmosis is not classified among the notifiable diseases,
hard data on the incidence and prevalence, as well as informa-
tion on its morbidity and mortality, should be considered frag-
mentary or simply not available inmany endemic areas [28, 29].
It is admitted that histoplasmosis occurs most commonly in
the Americas, since most of the studies are published from
patients residing in this area. But the organism exists in many
diverse areas around the world and is described in the non-
English literature [11, 28]. In North America, H. capsulatum
is endemic in the Mississippi and Ohio River valleys and also
in localized foci throughout the region [11, 30, 31]. In Central
and South America and the Caribbean area, it has been de-
scribed in almost all countries except Chile [4, 28, 32–34].
Other endemic areas include parts of Africa, Asia (India,
China, Philippines, Thailand) and Australia [7, 35–38].
In endemic areas, histoplasmosis represents the first man-
ifestation of AIDS in up to 50–75 % of patients and occurs in
about 2–25 % in HIV-infected patients living in these areas
[39]. Few incidence data using cohort studies are available. In
one endemic area, before the HAART era, subclinical or
symptomatic histoplasmosis occurred in 12/100 person-years
at risk in a cohort of HIV-infected patients [40]. Nowadays,
with the advent of effective antiretroviral therapy, North
American authors state that the disease is less frequently seen
in HIV-infected patients in USA [11]. Still, during the
HAART era, in one South American endemic area, histoplas-
mosis is the first AIDS-defining event with an incidence of
15,4/1000 HIV-infected person-years [41]. In disease-
endemic areas where research centers and/or reference centers
for the diagnosis led studies and published papers, physicians
are used to seeking and treating for histoplasmosis. Thus, at
the AIDS stage, histoplasmosis-related mortality is mainly
around 10 % during the HAART-era [24]. But, even in high-
income countries, in settings far from the reference centers’
influences and means, mortality increased up to 40 %. Apart
from the host’s medical history and socio-economic factors,
this observation is probably due to the lack of disease
recognition and knowledge by physicians who are unable to
diagnose earlier and treat a treatable disease [42].
Histoplasmosis occurs infrequently in persons living outside
of, and not travelling to, endemic areas.While precise incidence
figures are unavailable, the low incidence can be inferred from
case reports reviews on this subject [27]. In Europe, most of
these cases are considered as “imported”with exposure decades
before, when staying in or travelling to a known endemic
region [8–10]. Also, as described in the soil of the Po River
valley in Italy, microfoci contaminated withH. capsulatum can
be found in regions considered as non-endemic. These may be
the source of exposure causing autochtonous cases described in
several European countries [10]. Historically, mortality in non-
endemic areas was observed at around 50 to 60 % [8, 9]; but
since the availability of HAART, a marked decrease to almost
20 % was observed in some places [8].
Pathogenesis and Risk Factors in HIV-Infected Patients
H. capsulatum is a thermally dimorphic ascomycete,
displaying a filamentous mold form (saprophytic form) in
the environment and in culture at temperatures below 35 °C,
and a yeast phase (parasitic form) in tissue and body fluids at
temperatures above 35 °C. The mold phase may contain
macroconidia and microconidia. The latter, smooth walled
with a diameter of 2 to 4 μm, are the infectious particles.
The yeast phase develops as small oval budding cells with a
diameter of 2 to 4 μm, mainly observed within the macro-
phages. In Africa, the yeast phase described is mostly thick
walled and larger, 8 to 15 μm in diameter [18].
H. capsulatum is found in soils throughout the world. It
grows best in soils with high nitrogen content, particularly
those enriched with bird or bat guano. Birds do not become
colonized or infected with H. capsulatum (since their body
temperature is too high), and their droppings are primarily a
nutrient source for the development of fungal pathogen. Soil
samples from sites where birds have roosted have remained
contaminated for at least 10 years after the roost has been
cleared, even in urban areas [18, 43].
Upon disruption of soil containing the organism, infection
with H. capsulatum mainly develops when microconidia or
hyphal elements are inhaled and convert into yeasts in the lungs,
or when organisms in old foci of infection reactivate during
immunosuppression [44]. Once deposited in the lungs,
H. capsulatum is internalized by resident and recruited phago-
cytes, including macrophages, dendritic cells, and neutrophils.
The intracellular fate of the organism is divergent in these
cellular populations. While neutrophils and dendritic cells have
fungistatic and fungicidal activity, respectively, H. capsulatum
survives in macrophages prior to cellular activation regulating
the pH of the intraphagosomal environment. Phagocytes facili-
tate dissemination of H. capsulatum to several organs,
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throughout the mononuclear phagocyte system, including the
spleen, liver, bone marrow, and lymph nodes. Thus, to control
intracellular growth of the organism, the host must mount a
robust proinflammatory response, and cellular immunity plays
an essential role in defense against H. capsulatum [45].
Therefore, with the development of HIV-infection and the pro-
gressive impairment of cellular immunity, patients are at a higher
risk of disseminated and deadly infections with H. capsulatum.
In endemic areas, whether symptomatic diseases are caused
by reactivation of old foci or by a recent exogenous exposure
is unknown. Published data support reinfection in the context
of outbreaks or reactivation when calcified lymph nodes are
visualized on chest radiograms [39]. Recently, a time series
attempted to estimate if new infection is prevailing over
reactivation in endemic areas. Using climatic data, in one
endemic area, 70% of incident HIV-associated histoplasmosis
cases could be predicted compared to observed cases [44].
Also, a clear seasonality pattern in incident cases of histoplas-
mosis was described [46]. These studies are in favor of new
infection or reinfection rather than reactivation as the main
pathogenesis mechanism to explain the occurrence of symp-
tomatic histoplasmosis in endemic areas [44, 46].
Among Risk Factors Previously Studied in HIV-Infected
Patients, Occupational or Environmental Factors and Host
Factors Have Been Described
Environmental exposures to sources containing bat or bird
guano are known to increase the risk of histoplasmosis in the
general population, including histories of cave exploration,
wood cutting, or exposure to bird roosts, excavation sites,
farms or chicken coops [47]. In HIV-infected individuals
experiencing histoplasmosis, prospectively studied and com-
pared to control without histoplasmosis, a history of exposure
to chicken coops was found to be significantly associated with
histoplasmosis [47].
Current or prior occupations or activities with soil contam-
inated with bird or bat droppings have been described to be
associated with an increased risk of histoplasmosis [40, 48].
Host factors previously found to be independently associ-
ated with histoplasmosis are: low CD4 count (<200/mm3),
low CD4 count at the NADIR (<50/mm3), low CD8 count
(<650/mm3), absence of antiretroviral treatment or the first
6 months under antiretroviral therapy, a history of herpes
simplex infection, absence of systemic antifungal therapy
(fluconazole) and male gender [40, 49].
Out of H. capsulatum transmission to recipient by donor's
solid organ transplant, no direct interhuman contamination has
been previously described [50].
Clinical Findings
Although it is mostly asymptomatic and self-limiting in immu-
nocompetent persons, histoplasmosis in immunocompromised
HIV-infected patients presents as a symptomatic and dissemi-
nated infection in 95 % of the cases [11]. With the aggravation
of CD4 Lymphocyte decline, the evolution is rapid and always
fatal in the absence of treatment [2]. Thus, according to pub-
lished series, there is up to 39 % death following diagnosis in
endemic areas and 58 % death in non-endemic areas [9, 24].
During the HIV infection, the evolutive mode is very
variable, from extreme latency to a fulminant form. For 10–
20 % of patients, severe rapidly fatal forms are described.
These forms present as a septic shock with intravascular
disseminated coagulation, multiorgan failure (kidneys, liver,
lungs), and rhabdomyolysis, all of which may be associated
with a hemophagocytosis syndrome. These presentations of
unclear pathogenesis seem to be a late manifestation of histo-
plasmosis [39]. Mortality of these severe cases is very high,
with 50–70 % death [51].
Inflammatory reconstitution disease following antiretrovi-
ral treatment initiation has also been described [8, 52].
All organs and tissues may be clinically involved [11]. In
HIV-infected patients histoplasmosis is disseminated in 95 %
of the cases, and in 90% of the cases, it concerns patients with
CD4 counts below 200/mm3. A subacute presentation is the
most frequent, with symptoms evolving for 1 or 2 months,
during which the patient is seen by physicians. The clinical
picture is misleading, the symptoms being mostly nonspecific.
The general symptoms, particularly fever, fatigue and weight
loss, are almost always found. Respiratory symptoms such as
cough or dyspnea are observed in 50 % of the cases, and may
be associatedwith hepatosplenomegaly (25% of cases) and/or
superficial lymph node enlargement (25 % of cases).
Digestive, neurological or muco-cutaneous manifestations
are less frequent (10–20 % of cases) and polymorphous.
Isolated pulmonary manifestations have also been described
in less immunocompromised patients (CD4>200).
Pulmonary intersticial syndromes are often observed on chest
radiograms or computed tomography (CT) scans. This implies
that bronchoscopy must be performed to rule out the differ-
ential diagnosis of pneumocystosis [39].
Similarly to clinical symptoms, standard biology tests are
nonspecific. However, they may give elements to suspect the
diagnosis and lead to further investigations to confirm the
diagnosis. The elevation of lactate dehydrogenase (LDH),
liver enzymes (TGO, alkaline phosphatase), ferritin alone or
isolated with pancytopenia and/or hemophagocytosis syn-
drome, are classically described [39].
Thus, a high suspicion index is required from clinicians
because of the nonspecific nature of the clinical, biologic and
radiologic spectrum of histoplasmosis. In disease-endemic
areas, this nonspecific clinical picture makes tuberculosis the
main differential diagnosis of histoplasmosis. Numerous pub-
lications report cases of histoplasmosis mimicking tuberculosis
and state that making this differential diagnosis at the bed
patient is difficult; mainly because of the absence of diagnostic
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facilities or because a diagnosis of histoplasmosis was not
considered. Nevertheless, tuberculosis and histoplasmosis
could be easily distinguished, as reported recently. Numerous
AIDS-related death caused by histoplasmosis and mistaken for
multi-drug-resistant tuberculosis could be avoided [53].
Diagnosis
Direct examination of MGG-stained slides of all tissue or
body fluid is a simple and rapid diagnostic method. In dis-
seminated forms, smears obtained from tissue biopsies, bone
marrow aspiration, or peripheral blood are fairly contributive.
However, sensitivity varies according to the type of sample,
the severity of the disease and the experience of the operator.
With positive results for 50 to 75 % of patients, bone marrow
aspiration is the most contributive [24, 39]. Special staining
(PAS and Gomori Grocott) may be performed in pathology.
These stainings allow one to rule out the main differential
diagnoses, such as C. glabrata, P. marneffei, Leishmania,
Trypanosoma and other staining artifacts [24].
Certain diagnosis rests on the culture and identification of
Histoplasma capsulatum from any tissue or body fluid, ob-
tained mainly by using invasive procedures. The isolation in
culture is slow and may take several weeks (1–6 weeks).
Sabouraud’s dextrose agar media are thus incubated for sev-
eral weeks between 25 °C and 30 °C. The observation of
macronidia and micronidia are characteristic, but since they
are highly infectious, this must be performed in a Biosafety
Laboratory (BSL) level 2 or a BSL 3, according to the
country’s regulations. A definitive, specific and commercially
available DNA probe assay should always be performed to
confirm the diagnosis. The laborious task of converting the
mold phase to the yeast phase is no longer required for the
definitive identification of H. capsulatum [11].
Specificity is 100 %, but sensitivity varies between 85 and
90 % according to the fungal load and the laboratory experi-
ence [24, 54, 55]. Bone marrow aspirates yield the highest
proportion of positive cultures (70–90 %). For peripheral
blood culture, authors notably recommend the lysis-
centrifugation technique, in order to increase sensitivity and
to reduce the identification delay relative to other techniques
[39]. For the diagnosis of isolated neuro-meningeal forms, the
diagnosis must rely on other techniques, given the very low
sensitivity of cerebrospinal fluid (CSF) culture [54].
Antibody detection by immunodiffusion or complement
fixation is less sensitive in immunocompromised HIV-
infected patients than in immunocompetent patients (90 %)
[39, 54]. Serology is only positive in 50–70 % of immuno-
compromised HIV patients [39, 54]. The rise of antibody titers
is observed 2–6 weeks after exposure, and the lack of discrim-
ination between active and passive infection are not compat-
ible with the management of acute cases. However, serology
on CSF may be of interest for the diagnosis of neuro-
meningeal forms [56].
Immunodiffusion is more specific but less sensitive than
complement fixation. Cross-reactions with other fungal path-
ogens, lymphoma, sarcoidosis and tuberculosis have been
reported [57].
The detection of Histoplasma capsulatum var. capsulatum
circulating antigen may be performed with several EIA
methods.
The third generation polyclonal MVista Histoplasma anti-
gen EIA allows the quantitative detection of Histoplasma
polysaccharide circulating antigen with a sensitivity of 95–
100 % in urine and 92–100 % in serum [55, 58]. The antigen
levels detected are higher in the immunocompromised pa-
tients with a disseminated form. Moreover, the antigen level
seems correlated with the severity of the clinical presentation
(admission or not in ICU) [55]. Specificity is 99 %, and
positive and negative predictive values are 91 % and
99.5 %, respectively (for a 10 % prevalence) [58]. In pulmo-
nary forms of histoplasmosis, this test may be performed on
bronchioloalveolar lavage fluid with a 93 % sensitivity [59].
Despite the evolution of the test, there are still cross–reactions
with blastomycosis (90 %), paracoccidioidiomycosis or
penicilliosis (80%), coccidioidiomycosis (60%), aspergillosis
(10 %) and sporotrichosis [55, 60]. However, this method is
currently the best validated method for the diagnosis of histo-
plasmosis in HIV-infected patients. Not commercialized, it is
hardly used out of the USA [24, 61].
The IMMY ALPHA Histoplasma antigen EIA has been
marketed since 2006. Sensitivity is 71 % and specificity is
98 % in urine. Using the same detection and antigen capture
technique with polyclonal antigens, similar cross-reactions are
observed with fungal pathogens (Paracoccidioidiomycosis,
coccidioidiomycosis and blastomycosis) [62]. This first test
seems less utilized, having generated debates in the literature
[62–64]. However, recent modifications and the development
of monoclonal antibodies seem very promising [65, 66].
The Mycotic Disease Branch of the Centers for Disease
Control and Prevention (CDC) also developed an EIA
Histoplasma antigen detection method with a sensitivity of
81 % and a specificity of 95 % in the urine of HIV patients in
Guatemala. Cross-reactions were only observed for
paracoccidioidiomycosis [67]. This test is routinely used in
Colombia and is currently being evaluated on the Guiana
Shield (ClinicalTrials .gov Regist ra t ion number:
NCT01884779).
Since MVista test can’t be performed out of the MVista
laboratory in Indianapolis, the IMMY and CDC EIA tests
developments are of importance, because they are designed
to improve methods for the detection of Histoplasma
capsulatum in regions with limited resources where the or-
ganism is endemic and where delayed diagnosis of histoplas-
mosis results in high mortality rates.
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False positives have been observed with the Platelia
Aspergillus EIA (BioRad) in the serum of 50–70 % of patients
with confirmed histoplamosis [68–71]. This cross-reaction
may be of interest in hospitals that do not have access to
Histoplasma EIAs, by taking into consideration the epidemi-
ologic context and other potential causes of false positives in
the Platelia Aspergillus test [71].
The molecular diagnosis by Polymerase Chain Reaction
(PCR) gives rapid results with good sensitivity and specificity
in tissues and body fluids of HIV-infected patients [72, 73].
However, its place in patient care is not clear, since it has not
been externally validated and none of the methods have been
commercialized [57, 74]. Recently, a loop-mediated isother-
mal amplification (LAMP) assay, a potential inexpensive
point of care diagnostic tool, proved the concept that the assay
can be used to detectHistoplasma DNA in urine. Still, further
evaluation of this assay using body fluid samples from a larger
patient population is warranted [75].
Treatment
The treatment of Histoplasma capsulatum var. capsulatum
infection in HIV-infected patients has led to recommendations
in the USA and in France [76, 77]. However, there are few
recent data based on randomized controlled trials: the 2007
North American recommendations are still valid [78, 79].
While waiting for mycological confirmation of the diagno-
sis of a patient with a strong suspicion of histoplasmosis with
or without severity symptoms, clinicians have two options for
the treatment induction: intravenous (IV) amphotericin B or
oral itraconazole. Although amphotericin B is fungicidal and
has shown its efficacy in terms of survival, it is also nephro-
toxic [80]. Itraconazole is fungistatic and is associated with
drug interactions that complicate patient care in the context of
profound immunosuppression. This, added to the diminished
bioavailability of itraconazole in HIV patients, makes the
recommended serum concentration level long and difficult to
reach.
In a randomized clinical trial, IV liposomal amphotericin B
was more effective than deoxycholate amphotericin B, with a
quicker clinical response, a decreased toxicity, and a de-
creased mortality [80]. Thus, for the induction treatment of
moderately severe and severe presentations of disseminated
histoplasmosis, liposomal amphotericin B (3 mg/kg/day) is
the recommended strategy for 2 weeks or until clinical im-
provement. A relay with oral itraconazole (200 mg three times
a day for 3 days, then twice a day) must then be initiated for at
least one year [78].
In order to avoid overlooking presentations with high
short-term lethality, and to better guide treatment choice,
studies were led to identify risk factors associated with severe
histoplasmosis [40, 51]; these serve as the basis for the 2004
definition of histoplasmosis severity by the CDC [81]. Severe
cases of histoplasmosis were defined as patients presenting
one or more of the following criteria: temperature >39 °C,
systolic blood pressure <90 mmHg, arterial oxygen pressure
<70 mmHg, weight loss greater than 5 %, a Karnofsky score
<70, haemoglobin concentration <10 g/dL, neutrophil counts
<1000/mm3, platelet count <100 000/mm3, aspartate
aminotransférase >2.5 times the normal threshold, serum
bilirubine or creatinine exceeding twice the normal threshold,
albumine concentration < 3.5 g/dL, the presence of a coagu-
lopathy, the presence of another organ dysfunction or con-
firmed meningitis [81]. This definition seems scarcely used in
routine, and no severity score is available to guide clinicians in
their therapeutic choices.
In severe forms of histoplasmosis, renal failure is often
described: either associated with multiorgan failure, or sec-
ondary to amphotericin B nephrotoxicity. Thus, clinicians
tend to switch to itraconazole in order to not aggravate renal
failure. However, the poor prognosis of these clinical presen-
tations justifies the continuation of the most effective drug,
amphotericin B, despite its nephrotoxicity. Inmost cases, renal
function is restored ad integrum, despite the use of this neph-
rotoxic therapy [78].
For non-severe cases, itraconazole is the first-line treatment
with the same protocol as above. The response is positive in
85 % of the cases [82].
The surveillance of itraconazole concentrations is recom-
mended, notably when drug interactions are suspected (par-
ticularly with protease inhibitors, efavirenz or rifampicine).
The surveillance of serum concentrations must take place 7–
15 days following initiation. On a random blood sample, the
serum concentration of itraconazole must be >1 μg/mL [78].
In terms of intestinal absorption, the itraconazole syrup for-
mulation, prescribed in a fasting patient, seems preferable and
better tolerated than capsules prescribed during a meal [76].
The evaluation of treatment efficacy with the regular mon-
itoring of serum and urine Histoplama antigen concentrations
using MVista Histoplasma antigen EIA is only available and
recommended in the USA [76, 83]. For countries where this
test is not available, under some conditions, notably the
knowledge of the local epidemiology of cross-reacting fungal
infections, certain authors consider the use of the Platelia
Aspergillus EIA (BioRad) to monitor the therapeutic efficacy
of antifungals [68, 71].
Acute non-disseminated pulmonary presentations in HIV-
infected patients with CD4 counts >300/mm3 are treated like
immunocompetent individuals [78].
Confirmed neuro-meningeal HIV-associated histoplas-
mosis is initially treated with IV liposomal amphotericin
B (5 mg/kg/day) for 4–6 weeks. A relay with oral
itraconazole 200 mg two to three times per day is instated
for at least one year, and until the normalization of the
CSF abnormalities [78].
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Oral posaconazole and voriconazole are considered
second-line treatments for non-severe disseminated
histoplasmosis.[76]. Fluconazole is less effective than
itraconazole, but may be used as a second-line treatment in
itraconazole-intolerant patients at a dose of 800 mg/day [84].
Antiretroviral treatment must be introduced rapidly follow-
ing the initiation of the antifungal treatment. Immune reconsti-
tution inflammatory syndromes have been described, but are
mostly non-severe and are not considered sufficient to warrant
delaying antiretrovirals to restore cellular immunity, the key
defense against Histoplasma capsulatum infection [76, 78].
Prevention
Maintenance therapy (secondary prophylaxis) uses oral
itraconazole 200 mg/day. It must be continued for life if the
immunosuppression persists or if histoplasmosis relapses de-
spite an appropriate treatment. Primary prophylaxis with
itraconazole (200 mg daily) is recommended in HIV-infected
patients with CD4 cell counts <150 cells/mm3 in specific
areas of endemicity where the incidence of histoplasmosis is
>10 cases per 100 patient-years [78]. The USA is the only
endemic area recommending primary prophylaxis against his-
toplasmosis in immunosuppressed individuals, a strategy that
has recently been shown to be cost-effective, particularly in
low and middle income settings [85].
To our knowledge, the USA is also the only one to edit
detailed recommendations regarding occupational or environ-
mental exposure to protect workers at risk of histoplasmosis [86].
Recently, concerns about immunosuppressed travelers
have been published. These patients represent an increasing
group of travelers, for business or tourism. Those with severe
cellular immunodeficiency, like advanced HIV infection, dis-
play the highest risk of fungal infections. Thus, a systematic
visit in a travel clinic for immunocompromised patients trav-
eling to the tropics ensures that the specific risks of acquiring
fungal infections (and others) are understood. When immuno-
compromised hosts return to their area of residence, a
nonbacteriologically documented, potentially severe, febrile
pneumonia, with or without dissemination signs (skin lesions,
cytopenia) should alert for travel-acquired fungal infection,
even years after return. Localized subcutaneous nodule may
be also ascribed to fungal infection. Finally, infectious disease
physicians should be aware ofmajor clinical patterns of travel-
acquired fungal infection, as well as the fungi involved, and
risk factors according to the geographical area visited [87].
Conclusion
Nowadays, the real burden of histoplasmosis is not known, it is
only based on estimates and not on hard data. Histoplasmosis is
still a public health problem during the HAARTera, notably in
HIV-infected individuals. The medical mycological iceberg
statement, written 40 years ago, is still ongoing throughout
the world [29]. Outside of research centers or reference centers
for the diagnosis of histoplasmosis, in most of the countries
where it is endemic, the disease remains either mistaken for
tuberculosis or neglected. There are still research needs and
accomplishments to target in order to better understand, diag-
nose and treat individuals infected with H. capsulatum. “Know
your epidemic, know your response”; it is time to act against
histoplasmosis [15, 17].
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